Gastro-esophageal Reflux Disease (GERD) Completed Phase 2 Trials for Rabeprazole (DB01129)

Also known as: Gastroesophageal Reflux Disease / Gastro-esophageal Reflux Disease / GERD / GERD Gastroesophageal Reflux Disease / Gastro-Oesophageal Reflux Disease / Gastrooesophageal reflux disease / GERD (Gastroesophageal Reflux Disease) / Esophageal Reflux / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Gastro-esophageal Reflux Diseases / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00222170Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)Treatment
NCT00132496Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleTreatment
NCT00165841Maintenance Intermittent Therapy for Symptomatic GERD PatientsTreatment